Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period. Issue 1 (10th September 2022)

• Record Type: Journal Article
• Authors: Woo, Peter Y M; Yau, Stephen; Lam, Tai-Chung; Pu, Jenny K S; Li, Lai-Fung; Lui, Louisa C Y; Chan, Danny T M; Loong, Herbert H F; Lee, Michael W Y; Yeung, Rebecca; Kwok, Carol C H; Au, Siu-Kie; Tan, Tze-Ching; Kan, Amanda N C; Chan, Tony K T; Mak, Calvin H K; Mak, Henry K F; Ho, Jason M K; Cheung, Ka-Man; Tse, Teresa P K; Lau, Sarah S N; Chow, Joyce S W; El-Helali, Aya; Ng, Ho-Keung; Poon, Wai-Sang
• Is Part Of: Neuro-oncology practice. Volume 10:Issue 1(2023)
• Page Start: 50
• Page End: 61
• Publication Date: 2022-09-10
• Subjects: age standardized incidence rate -- Chinese -- glioblastoma -- overall survival -- temozolomide chemoradiotherapy; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481005
• DOI: 10.1093/nop/npac069
• Languages: English
• ISSNs: 2054-2577

Abstract

Abstract: Background: The aim of this study is to address the paucity of epidemiological data regarding the characteristics, treatment patterns and survival outcomes of Chinese glioblastoma patients. Methods: This was a population-level study of Hong Kong adult ( > 18 years) Chinese patients with newly diagnosed histologically confirmed glioblastoma between 2006 and 2019. The age standardized incidence rate (ASIR), patient-, tumor- treatment-related characteristics, overall survival (OS) as well as its predictors were determined. Results: One thousand and ten patients with a median follow-up of 10.0 months were reviewed. The ASIR of glioblastoma was 1.0 per 100 000 population with no significant change during the study period. The mean age was 57 + 14 years. The median OS was 10.6 months (IQR: 5.2–18.4). Independent predictors for survival were: Karnofsky performance score > 80 (adjusted OR: 0.8; 95% CI: 0.6–0.9), IDH-1 mutant (aOR: 0.7; 95% CI: 0.5–0.9) or MGMT methylated (aOR: 0.7; 95% CI: 0.5–0.8) glioblastomas, gross total resection (aOR: 0.8; 95% CI: 0.5–0.8) and temozolomide chemoradiotherapy (aOR 0.4; 95% CI: 0.3–0.6). Despite the significant increased administration of temozolomide chemoradiotherapy from 39% (127/326) of patients in 2006–2010 to 63% (227/356) in 2015–2019 ( P -value < .001), median OS did not improve (2006–2010: 10.3 months vs 2015–2019: 11.8 months) (OR: 1.1; 95% CI: 0.9–1.3). Conclusions: The incidence of glioblastoma in the Chinese general population is low. We charted the development of neuro-oncological care of glioblastoma patients in Hong Kong during the temozolomide era. Although there was an increased adoption of temozolomide chemoradiotherapy, a corresponding improvement in survival was not observed.